Fostamatinib: observing safety, thrombosis, and efficacy on raising platelets in immune thrombocytopenia: protocol for a multicenter, prospective, single-arm study (FOSTER-ITP study)
Frontiers in Drug Discovery · 20.11.2026 · 6
DOI: 10.3389/fddsv.2026.1937013 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Frontiers in Drug Discovery, online erschienen am 20.11.2026. Verfasst von Yoshitaka Miyakawa und 8 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet destruction and impaired platelet production. Although treatment has traditionally focused on preventing bleeding, patients with ITP, particularly those with antiphospholipid antibodies (aPL) or a history of thrombosis, are at increased risk of thromboembolic events. Patients with ITP at high thrombotic risk have not been the primary focus of previous clinical trials, and evidence to guide treatment in this population remains limited.
Methods
The FOSTER-ITP study is a multicenter, prospective, single-arm study designed to evaluate the efficacy and safety of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in adults with persistent or chronic primary ITP at high thrombotic risk. Eligible patients have platelet counts <30,000/μL despite previous ITP treatment and either aPL positivity documented within 12 months before informed consent or a history of thrombosis. Participants will receive fostamatinib for 24 weeks. The primary endpoint is achievement of a platelet count ≥50,000/μL between weeks 16 and 24. Secondary endpoints include platelet response, bleeding events, adverse events, and thrombotic events. Exploratory analyses will assess plasma thrombopoietin concentrations, immature platelet fraction, 7-color flow cytometry-based B-cell immunophenotypes (naïve, memory, plasmablast, transitional, mature B), and anti-GPIIb/IIIa (CD41) antibody-producing B cells.
Discussion
By inhibiting SYK-dependent pathways involved in platelet destruction and autoreactive B-cell responses, fostamatinib may offer a mechanistically distinct option for ITP patients in whom both bleeding and thrombosis must be considered. This study is expected to provide prospective clinical and immunological evidence regarding fostamatinib in Japanese patients with high thrombotic risk ITP. Ethics and dissemination The study was approved by the Clinical Research Review Board of Saitama Medical University and registered in the Japan Registry of Clinical Trials (jRCTs031250344).
Zitieren
APA
Miyakawa, Y., Kashiwagi, H., Abe, R., Yokoyama, K., Yamanouchi, J., Kato, H., Kawasaki, Y., Katoh, M., & Kuwana, M. (2026). Fostamatinib: observing safety, thrombosis, and efficacy on raising platelets in immune thrombocytopenia: protocol for a multicenter, prospective, single-arm study (FOSTER-ITP study). Frontiers in Drug Discovery, 6. https://doi.org/10.3389/fddsv.2026.1937013
Vancouver
Miyakawa Y, Kashiwagi H, Abe R, Yokoyama K, Yamanouchi J, Kato H, et al. Fostamatinib: observing safety, thrombosis, and efficacy on raising platelets in immune thrombocytopenia: protocol for a multicenter, prospective, single-arm study (FOSTER-ITP study). Frontiers in Drug Discovery. 2026;6. doi:10.3389/fddsv.2026.1937013
BibTeX
@article{Miyakawa2026,
author = {Miyakawa, Yoshitaka and Kashiwagi, Hirokazu and Abe, Ryohei and Yokoyama, Kenji and Yamanouchi, Jun and Kato, Hisashi and Kawasaki, Yohei and Katoh, Makoto and Kuwana, Masataka},
title = {Fostamatinib: observing safety, thrombosis, and efficacy on raising platelets in immune thrombocytopenia: protocol for a multicenter, prospective, single-arm study (FOSTER-ITP study)},
journal = {Frontiers in Drug Discovery},
year = {2026},
volume = {6},
doi = {10.3389/fddsv.2026.1937013}
}
EUVIMED